Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 3:58 PM ET

Biotechnology

Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

16745 West Bernardo Drive

Suite 200

San Diego, CA 92121

United States

Founded in 2005

25 Employees

Phone:

858-376-2600

Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $460.0K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 57
Total Annual Compensation: $325.6K
Executive Vice President of Clinical Development
Age: 60
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2014.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Conatus Pharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported interest income was $17,977 against $15,343 a year ago. Net loss was $6,057,254 against $5,303,024 a year ago. Net loss per share, basic and diluted was $0.31 against $0.34 a year ago. For the six months, the company reported interest income was $29,396 against $36,116 a year ago. Net loss was $12,036,918 against $10,546,380 a year ago. Net loss per share, basic and diluted was $0.69 against $0.68 a year ago.

Conatus Pharmaceuticals Inc. to Report Q2, 2015 Results on Aug 05, 2015

Conatus Pharmaceuticals Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 05, 2015

Conatus Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 05, 2015

Conatus Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 05, 2015

Similar Private Companies By Industry

Company Name Region
Alkira Therapeutics, Inc. United States
ProMed Pharma, LLC United States
TransGenex Nanobiotech, Inc. United States
Prospex Medical III, Inc. United States
Nutraceutical Research Innovations LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Conatus Pharmaceuticals Inc., please visit www.conatuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.